These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Weisman HF; Bartow T; Leppo MK; Boyle MP; Marsh HC; Carson GR; Roux KH; Weisfeldt ML; Fearon DT Trans Assoc Am Physicians; 1990; 103():64-72. PubMed ID: 2132543 [TBL] [Abstract][Full Text] [Related]
8. Enhanced recovery of ischemic myocardium by combining percutaneous bypass with intraaortic balloon pump support. Lazar HL; Treanor P; Yang XM; Rivers S; Bernard S; Shemin RJ Ann Thorac Surg; 1994 Mar; 57(3):663-7; discussion 667-8. PubMed ID: 8147638 [TBL] [Abstract][Full Text] [Related]
9. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Shandelya SM; Kuppusamy P; Herskowitz A; Weisfeldt ML; Zweier JL Circulation; 1993 Dec; 88(6):2812-26. PubMed ID: 8252695 [TBL] [Abstract][Full Text] [Related]
10. Role of leukocyte depletion during cardiopulmonary bypass and cardioplegic arrest. Lazar HL; Zhang X; Hamasaki T; Treanor P; Rivers S; Bernard S; Shemin RJ Ann Thorac Surg; 1995 Dec; 60(6):1745-8. PubMed ID: 8787474 [TBL] [Abstract][Full Text] [Related]
11. Reduction of infarct size with coronary venous retroperfusion. Lazar HL; Haan CK; Yang X; Rivers S; Bernard S; Shemin RJ Circulation; 1992 Nov; 86(5 Suppl):II352-7. PubMed ID: 1358475 [TBL] [Abstract][Full Text] [Related]
12. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Gillinov AM; DeValeria PA; Winkelstein JA; Wilson I; Curtis WE; Shaw D; Yeh CG; Rudolph AR; Baumgartner WA; Herskowitz A Ann Thorac Surg; 1993 Mar; 55(3):619-24. PubMed ID: 8383955 [TBL] [Abstract][Full Text] [Related]
13. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Chai PJ; Nassar R; Oakeley AE; Craig DM; Quick G; Jaggers J; Sanders SP; Ungerleider RM; Anderson PA Circulation; 2000 Feb; 101(5):541-6. PubMed ID: 10662752 [TBL] [Abstract][Full Text] [Related]
14. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Pierre AF; Xavier AM; Liu M; Cassivi SD; Lindsay TF; Marsh HC; Slutsky AS; Keshavjee SH Transplantation; 1998 Sep; 66(6):723-32. PubMed ID: 9771835 [TBL] [Abstract][Full Text] [Related]
15. Does off-pump revascularization reduce coronary endothelial dysfunction? Lazar HL; Bao Y; Rivers S J Card Surg; 2004; 19(5):440-3. PubMed ID: 15383057 [TBL] [Abstract][Full Text] [Related]
16. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Weisman HF; Bartow T; Leppo MK; Marsh HC; Carson GR; Concino MF; Boyle MP; Roux KH; Weisfeldt ML; Fearon DT Science; 1990 Jul; 249(4965):146-51. PubMed ID: 2371562 [TBL] [Abstract][Full Text] [Related]
17. Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Zacharowski K; Otto M; Hafner G; Marsh HC; Thiemermann C Br J Pharmacol; 1999 Nov; 128(5):945-52. PubMed ID: 10556930 [TBL] [Abstract][Full Text] [Related]
18. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. Khan TA; Bianchi C; Voisine P; Feng J; Baker J; Hart M; Takahashi M; Stahl G; Sellke FW J Thorac Cardiovasc Surg; 2004 Oct; 128(4):602-8. PubMed ID: 15457162 [TBL] [Abstract][Full Text] [Related]
19. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Homeister JW; Lucchesi BR Annu Rev Pharmacol Toxicol; 1994; 34():17-40. PubMed ID: 8042849 [TBL] [Abstract][Full Text] [Related]